Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 11, No 5 (2015) Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism Abstract  similar documents
A. V. Rudakova
"... Aim. To assess the cost-effectiveness of apixaban in the treatment and secondary prevention ..."
 
Vol 11, No 1 (2015) PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... apixaban is expected to be cost-effective alternative from the Russian Federation national healthcare ..."
 
Vol 11, No 6 (2015) Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events Abstract  similar documents
O. V. Shatalova
"... (bleeding) in the conventional therapy group was 4.8 times higher than the costs in apixaban group ..."
 
Vol 10, No 3 (2014) COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION Abstract  similar documents
A. V. Rudakova, V. A. Parfenov
"... in patients with NVAF in the Russian Federation. Aim. To evaluate the cost-effectiveness ratio of apixaban ..."
 
Vol 13, No 1 (2017) CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova
"... with "decision tree" modeling is performed. The costs of regimens using rivaroxaban and apixaban were calculated ..."
 
Vol 13, No 5 (2017) DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov
"... антикоагулянтами (НОАК). Основой  для подобных суждений стала сводная таблица лекарственных взаимодействий НОАК из ..."
 
Vol 11, No 3 (2015) ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... can be explained by both the lower cost of apixaban in comparison with reference drugs ..."
 
Vol 14, No 2 (2018) NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING Abstract  similar documents
Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov
"... . In comparison of different DOACs against each other apixaban demonstrated lower bleeding risk while patients ..."
 
Vol 12, No 4 (2016) Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true Abstract  similar documents
Yu. A. Bunin, S. V. Miklishanskaya
"... явилась разработка новых оральных антикоагулянтов (НОАК). В статье представлен современный взгляд на ..."
 
Vol 16, No 1 (2020) Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice Abstract  similar documents
A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko
"... терапии. При поступлении в стационар 60 (14%) больных получали оральные не-антагонисты витамина К (НОАК ..."
 
Vol 14, No 3 (2018) APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN Abstract  similar documents
O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova
"... of efficacy and safety of apixaban in patients with AF, depending on the presence of CHD, PAD, concomitant use ..."
 
Vol 11, No 3 (2015) PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT Abstract  similar documents
A. V. Rudakova
"... of major bleedings was similar for all treatment regiments. Apixaban reduced the cost of treatment ..."
 
Vol 16, No 1 (2020) The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation Abstract  similar documents
A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva
"... , rivaroxaban – in 41.3% (n=178), apixaban – in 20.2% (n=87) of patients. Results. The incidence of new cases ..."
 
Vol 14, No 4 (2018) Hepatotoxicity of New Oral Anticoagulants Abstract  similar documents
A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin
"... антикоагулянтов (НОАК) по зарегистрированным показаниям, и проанализировать опубликованные клинические случаи ..."
 
Vol 12, No 3 (2016) THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE Abstract  PDF (Eng)  similar documents
A. V. Kryukov, D. A. Sychev, D. A. Andreev, A. V. Ryabova, N. P. Denisenko, M. A. Loskutnikov, O. I. Vinogradov, M. A. Domashenko
"... Aim. To study pharmacokinetics of apixaban in patients with atrial fibrillation and cardioembolic ..."
 
Vol 11, No 5 (2015) Practical aspects of apixaban use in clinical practice: continuing the theme Abstract  similar documents
S. N. Bel'diev
"... Currently there are no generally accepted guidelines for the use of apixaban together with CYP3A4 ..."
 
Vol 15, No 2 (2019) Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova
 
Vol 10, No 3 (2014) EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION Abstract  similar documents
"... European Medicines Agency approved apixaban use in cardioversion. ..."
 
Vol 11, No 2 (2015) PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST Abstract  similar documents
D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii
"... Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base ..."
 
Vol 16, No 2 (2020) The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality Abstract  similar documents
B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov
 
Vol 13, No 1 (2017) DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT Abstract  similar documents
D. А. Napalkov, A. A. Sokolova, V. V. Fomin
"... anticoagulants, apixaban is associated with the best adherence to treatment and lowest bleeding incidence ..."
 
Vol 13, No 3 (2017) PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION Abstract  similar documents
A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko
"... 1045642 polymorphisms. ABCB1 gene rs4148738 polymorphism was associated with higher apixaban peak ..."
 
Vol 7, No 5 (2011) ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES Abstract  similar documents
Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy
 
Vol 9, No 3 (2013) ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT Abstract  similar documents
E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts
 
Vol 9, No 4 (2013) COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS Abstract  similar documents
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova
"... Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban ..."
 
Vol 10, No 4 (2014) NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY Abstract  similar documents
D. A. Napalkov, A. A. Sokolova
"... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..."
 
Vol 15, No 5 (2019) Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review Abstract  similar documents
B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov
 
Vol 7, No 3 (2011) COSTS OF THE HEALTH CARE IN RUSSIA ASSOCIATED WITH SMOKING Abstract  similar documents
A. V. Kontsevaya, A. M. Kalinina
"... Aim. To analyze costs of health care in Russia associated with smoking in 2009. Material ..."
 
Vol 13, No 6 (2017) PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS Abstract  similar documents
A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin
"... – rivaroxaban and apixaban) were included into the cohort study in parallel groups. In addition to evaluate ..."
 
Vol 14, No 3 (2018) THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE Abstract  similar documents
I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin
"... long-term anticoagulant therapy with apixaban in a full dose (5 mg b.i.d.), and the patient ..."
 
Vol 15, No 4 (2019) Optimization of Pharmacotherapy with Direct Oral Anticoagulants: the Need to Choose the Right Dosage Regimen Abstract  similar documents
A. I. Kochetkov, O. D. Ostroumova
"... profile and multimorbidity. In these terms, apixaban stands high among the DOAC class, and its high ..."
 
Vol 12, No 2 (2016) ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? Abstract  similar documents
D. A. Napalkov, A. A. Sokolova, A. V. Rodionov
"... and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic ..."
 
Vol 15, No 6 (2019) Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation Abstract  similar documents
M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin
"... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..."
 
Vol 16, No 2 (2020) Off-Label Medicines Use: Complex Problem of Modern Clinical Practice Abstract  similar documents
S. R. Gilyarevskiy
 
Vol 5, No 5 (2009) THE COMPARATIVE COST-EFFICACY ANALYSIS OF VARIOUS ANTIHYPERTENSIVE THERAPIES Abstract  similar documents
S. V. Malchikova, E. I. Tarlovskaya
"... Aim. To perform the comparative cost-efficacy analysis of various antihypertensive therapies ..."
 
Vol 8, No 1 (2012) ANALYSIS OF COST STRUCTURE FOR PHARMACOTHERAPY OF PATIENTS WITH STABLE ANGINA (THE CASE OF CARDIOLOGY DEPARTMENT OF TVER REGIONAL CLINICAL HOSPITAL) Abstract  similar documents
M. A. Demidova, N. N. Kirilenko
"... Aim. To analyze the cost structure for pharmacotherapy of patients with stable angina (SA ..."
 
Vol 12, No 5 (2016) Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease Abstract  similar documents
I. S. Daabul, A. A. Sokolova, D. A. Napalkov
 
Vol 16, No 3 (2020) Clinical and Pathophysiological Aspects of the Effect of Anticoagulants on Bone Tissue Abstract  similar documents
O. D. Ostroumova, I. V. Goloborodova
 
Vol 15, No 4 (2019) According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention Abstract  similar documents
Company Pfizer
 
Vol 7, No 5 (2011) ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
Yu. B. Belousov, I. S. Yavelov, D. Yu. Belousov, E. V. Afanasieva
"... . The study was performed based on methodology for Cost of Illness evaluation. Expenses associated with INR ..."
 
Vol 15, No 6 (2019) Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study) Abstract  similar documents
S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, S. N. Tolpygina, V. P. Voronina, N. A. Dmitrieva, O. V. Lerman, N. A. Komkova
"... recommended the use of rivaroxaban; 47 (23.4%) – the use of dabigatran and 43 (21.4%) – the use of apixaban ..."
 
Vol 8, No 3 (2012) PHARMACOECONOMIC ASPECTS OF NICOTINE ADDICTION TREATMENT IN PATIENTS WITH ANGINA REQUIRING CARDIAC SURGERY Abstract  similar documents
A. V. Rudakova, M. S. Berezhnova
"... the rejection of it are an important part of the treatment. Aim. To analyze the cost effectiveness ..."
 
Vol 8, No 1 (2012) CHANGES IN THE COSTS OF HYPERTENSIVE CRISIS THERAPY DUE TO OPTIMIZATION OF DRUG SUPPLY IN THE PRE-ADMISSION CARE Abstract  similar documents
N. I. Gaponova, N. F. Plavunov, V. L. Baratashvili
"... Aim. To assess the changes in the costs of treatment of patients with hypertensive crisis (HC ..."
 
Vol 6, No 4 (2010) ECONOMIC EFFICIENCY OF THE IMPLEMENTATION OF THE PROGRAM OF CARDIOVASCULAR DISEASES MULTIFACTORIAL PREVENTION IN THE ORGANIZED COLLECTIVE OF TECHNICAL RESEARCH INSTITUTE Abstract  similar documents
A. V. Kontsevaya, A. M. Kalinina, S. V. Belonosova, J. M. Pozdnjakov, M. B. Khudyakov
"... consultation. Costs associated with cardiovascular diseases and risk factors (medical care consumption ..."
 
Vol 9, No 4 (2013) COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE Abstract  similar documents
L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky
"... Aim. To compare direct medical costs of dabigatran and warfarin therapy in patients with non ..."
 
Vol 4, No 3 (2008) INFLUENCE OF HEALTH SCHOOL TRAINING OF PATIENTS WITH ISCHEMIC HEART DISEASE ON PHARMACOTHERAPY PROFILE AND COST (АВС/VEN ANALYSIS) Abstract  similar documents
A. V. Kontsevaja, А. М. Kalinina, E. J. Spivak
"... Aim. To study influence of patient training in Health School on pharmacotherapy profile and cost ..."
 
Vol 12, No 5 (2016) Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation Abstract  similar documents
N. A. Novikova, A. N. Volovchenko
"... showed the efficacy and safety of rivaroxaban and apixaban in preparation and performance of electrical ..."
 
Vol 13, No 5 (2017) WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT Abstract  similar documents
S. Yu. Martsevich, Y. V. Lukina
"...   of new OAC (NOAC) also appeared. In Russia, dabigatran, rivaroxaban and apixaban have been registered ..."
 
Vol 7, No 2 (2011) COST-EFFECTIVENESS EVALUATION OF PREHOSPITAL THROMBOLYSIS WITH TENECTEPLASE Abstract  similar documents
V. V. Omel'yanovskiy, E. V. Derkach, P. M. Khaylov, S. N. Tereshchenko
"... Aim. To evaluate clinical and cost effectiveness of different reperfusion strategies in myocardial ..."
 
Vol 11, No 4 (2015) EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME Abstract  similar documents
A. V. Rudakova, N. V. Lomakin
"... . To assess the cost-effectiveness of VerifyNow P2Y12 platelet reactivity testing in patients after ACS ..."
 
Vol 15, No 5 (2019) Costs and Evaluation of Vital and Essential Medicines for Internal Diseases Treatment, Purchased by Medical Organizations with the Funding from the System of Obligatory Medical Insurance in 2017 Abstract  similar documents
O. M. Drapkina, A. V. Kontsevaya, M. V. Sura, R. N. Shepel, L. M. Zhamalov
"... Aim. To assess the cost and importance of the vital and essential medicines for the treatment ..."
 
Vol 7, No 2 (2011) SOCIO-ECONOMIC DAMAGE BY ACUTE CORONARY SYNDROME IN RUSSIAN FEDERATION Abstract  similar documents
A. V. Kontsevaya, A. M. Kalinina, I. E. Koltunov, R. G. Oganov
"... . Material and Methods. Direct costs and economic losses associated with ACS were estimated. The structure ..."
 
Vol 14, No 2 (2018) PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS Abstract  similar documents
S. K. Zyryanov, A. E. Cheberda, D. Yu. Belousov
"... of treatment and clinical practice results was built. Cost-effectiveness analysis was done by comparing two ..."
 
Vol 9, No 2 (2013) ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES Abstract  similar documents
Z. M. Safiullina, S. V. Shalaev
"... inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial ..."
 
Vol 14, No 2 (2018) ECONOMIC BURDEN OF CARDIOVASCULAR DISEASES IN THE RUSSIAN FEDERATION IN 2016 Abstract  PDF (Eng)  similar documents
A. N. Kontsevaya, O. M. Drapkina, Yu. A. Balanova, A. E. Imaeva, E. I. Suvorova, M. B. Khudyakov
"... (RF) in 2016, including the direct costs and the economic losses caused by reduced productivity ..."
 
Vol 16, No 2 (2020) The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment Abstract  similar documents
К. V. Lobastov, I. V. Schastlivtsev
"... patients have been published: SELECT-D (rivaroxaban), HOKUSAI-VTE Cancer (edoxaban), ADAM VTE (apixaban ..."
 
Vol 14, No 3 (2018) ECONOMIC BURDEN OF HYPERCHOLESTEROLEMIA IN THE RUSSIAN FEDERATION Abstract  similar documents
A. V. Kontsevaya, Yu. A. Balanova, A. E. Imaeva, M. B. Khudyakov, O. I. Karpov, O. M. Drapkina
"... includes not only cost of its correction, but also the cost of treatment of diseases and complications ..."
 
Vol 8, No 1 (2012) PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov
"... the cost-effectiveness of dabigatran etexilate versus warfarin prescribed in “real-world” settings from ..."
 
Vol 14, No 2 (2018) WHAT DO PATIENTS WITH ATRIAL FIBRILLATION KNOW ABOUT STROKE AND SYSTEMIC EMBOLISM PREVENTION? DATA OF THE PRIMA-TERRA REGISTRY Abstract  similar documents
R. М. Linchak, O. G. Kompaniyets, A. M. Nedbaykin
"... . The main reason limiting the widespread use of NOACs is the high cost of these drugs. Conclusion ..."
 
Vol 12, No 2 (2016) THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE Abstract  similar documents
S. V. Moiseev
"... New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin ..."
 
Vol 10, No 2 (2014) PRIMARY PREVENTION OF MYOCARDIAL INFARCTION IN MIDDLE-AGED MALES (15-YEAR FOLLOW-UP): CLINICAL AND ECONOMIC ASPECTS OF THE PROBLEM Abstract  PDF (Eng)  similar documents
A. M. Kalinina, A. V. Kontsevaya
"... . Cost-effectiveness of primary prevention, including the one of MI, has been conclusively showed ..."
 
Vol 15, No 5 (2019) Findings Released from NAXOS Analysis. Pfizer Company Press Release Abstract  similar documents
article Editorial
"... Компания Pfizer представила результаты когортного исследования NAXOS (EvaluatioN of ApiXaban in ..."
 
Vol 7, No 4 (2011) VALUE OF THERAPEUTIC EQUIVALENCE IN SUBSTITUTION OF ORIGINAL DRUG WITH GENERIC BY EXAMPLE OF FOSINIPRIL Abstract  similar documents
N. P. Kutishenko, S. Yu. Martsevich, Zh. D. Kobalava, E. K. Shavarova
"... with arterial hypertension (HT) of 1-2 degrees, and to evaluate the cost effectiveness of original drug ..."
 
Vol 16, No 1 (2020) Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients Abstract  similar documents
A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin
"... therapy turned out to be the most promising for clinical use, since studies with dabigatran and apixaban ..."
 
Vol 10, No 6 (2014) THE ASSESSMENT OF COMPLIANCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION ACCORDING TO THE PROFILE REGISTER Abstract  similar documents
S. Y. Martsevich, A. R. Navasardyan, N. P. Kutishenko, A. V. Zakharova, V. P. Voronina, N. A. Dmitrieva, L. Yu. Lrozdova, A. V. Zagrebelnyy, O. V. Lerman, Yu. V. Lukina, G. V. Martynova, A. A. Nikulina, G. S. Ryazanova, A. Yu. Suvorov, S. N. Tolpygina
"... антикоагулянтов (НОАК) у пациентов с фибрилляцией предсердий (ФП) и выявить факторы, влияющие на нее. Материал и ..."
 
Vol 5, No 3 (2009) CLINICAL AND ECONOMICAL RATIONALES OF CARDIOVASCULAR RISK EVALUATION AT WORKPLACE Abstract  similar documents
A. V. Kontsevaya, A. M. Kalinina, Yu. M. Pozdnyakov, S. V. Belonosova, M. B. Khudyakov
"... (with estimation of the total costs, costs for one studied person and costs for revealing of one person needed ..."
 
Vol 9, No 1 (2013) PHARMACOEPIDEMIOLOGICAL AND PHARMACOECONOMIC STUDIES OF ANTIHYPERTENSIVE TREATMENT IN RUSSIA. Analytical Review Abstract  similar documents
T. S. Romanenko, A. V. Kontsevaya, S. V. Fitilev
"... therapy, conducted during the last decades inRussia. Despite the increased interest to the issue of cost ..."
 
Vol 3, No 4 (2007) THE ALGORITHMIC MODEL OF LABORATORY DIAGNOSTICS OPTIMIZATION Abstract  similar documents
G. I. Nazarenko, O. V. Andropova
"... of algorithmic approach is able to optimize diagnostics and its costs. Various algorithmic models, their features ..."
 
Vol 14, No 4 (2018) Risk Controlling of Gastrointestinal Bleeding in Comorbid Patients with Cardiovascular Diseases Abstract  similar documents
O. Yu. Chizhova, L. N. Belousova, I. G. Bakulin
"... не витамин К оральные антикоагулянты (НОАК), ранее известные как новые оральные антикоагулянты. За ..."
 
Vol 12, No 1 (2016) Pharmacoeconomic analysis of heart rate slowing drugs in patients with ischemic heart disease Abstract  similar documents
E. I. Tarlovskaya, T. I. Chudinovskikh
"... Aim. To compare the efficacy and cost/effectiveness ratio of the original and generic bisoprolol ..."
 
Vol 12, No 4 (2016) The use of oral anticoagulants in patients with atrial fibrillation: cohort study data Abstract  similar documents
O. V. Gaisenok, A. S. Leonov
"... .ч. новых ОАК (НОАК), в зависимости от типа ФП и причины неназначения этих препаратов. Результаты. Частота ..."
 
Vol 12, No 3 (2016) THE ADVANCED TACTICS OF THE MANAGEMENT OF PATIENTS WITH VENOUS THROMBOEMBOLISM: THE ROLE OF RIVAROXABAN AT VARIOUS STAGES OF TREATMENT Abstract  PDF (Eng)  similar documents
S. R. Gilyarevskiy
"... также выбор антикоагулянтов, в том числе новых пероральных антикоагулянтов (НОАК). Подробно ..."
 
Vol 8, No 2 (2012) PRELIMINARY RESULTS OF COMPARATIVE PHARMACOECONOMIC PROSPECTIVE STUDY OF DIFFERENT THERAPIES OF ARTERIAL HYPERTENSION Abstract  similar documents
E. I. Tarlovskaya, N. S. Maksimchuk, S. V. Malchikova, M. V. Avksentieva
"... (LVMI) were considered. Cost-effectiveness method of analysis was used. Results. In V/A group 75 ..."
 
Vol 7, No 1 (2011) THE CHOICE OF THE DRUG AMLODIPINE FOR THE HYPERTENSION TREATMENT FROM THE STANDPOINT OF ECONOMIC FEASIBILITY Abstract  similar documents
S. Yu. Martsevich, N. A. Dmitrieva, A. D. Deev, Yu. V. Lukina, L. A. Sokolova, V. V. Yakusevich
"... Aim. Тo compare the cost-effectiveness of antihypertensive therapy based on a generic and original ..."
 
Vol 9, No 1 (2013) CLINICAL AND COST EFFECTIVENESS OF PREVENTIVE COUNSELING OF YOUNG PATIENTS WITH ARTERIAL HYPERTENSION IN PRIMARY HEALTH CARE Abstract  similar documents
M. I. Shupina, O. Ju. Korennova, E. N. Loginova
"... Aim. To study clinical and cost effectiveness of training of young patients with arterial ..."
 
Vol 14, No 5 (2018) Economic losses due to low coverage of lipid-lowering therapy in patients with cardiovascular diseases in the Russian Federation Abstract  similar documents
Yu. A. Balanova, A. V. Kontsevaya, A. E. Imaeva, O. I. Karpov, M. B. Khudyakov
"... in 2016, including direct costs of the health care system  and indirect economic losses due to premature ..."
 
Vol 12, No 1 (2016) Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis Abstract  similar documents
V. I. Petrov, O. V. Shatalova, V. S. Gorbatenko, O. N. Smuseva, A. S. Maslakov
"... Цель. Анализ эффективности и безопасности новых пероральных антикоагулянтов (НОАК) в сравнении со ..."
 
Vol 10, No 6 (2014) THE PROBLEM OF THE USE OF NEW ORAL ANTICOAGULANTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY Abstract  similar documents
A. A. Rumyantsev, I. A. Pokataev, T. V. Kozlov, N. A. Rumyantsev
"... ВТЭ в онкологии сопровождается рядом проблем. Новые оральные антикоагулянты (НОАК) являются ..."
 
Vol 6, No 4 (2010) PHARMACOECONOMIC ANALYSIS OF CARVEDILOL THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC RISK FACTORS (ACCORDING TO THE CAMELLIA STUDY) Abstract  similar documents
S. Y. Martsevich, N. P. Kutishenko, A. D. Deev, S. A. Shalnova, R. G. Oganov
"... Aim. To perform cost-effectiveness analysis of 24 weeks antihypertensive therapy based ..."
 
Vol 10, No 4 (2014) RATIONAL PHARMACOTHERAPY BASED ON PHARMACOECONOMIC DATA AUDIT: PRINCIPLES AND APPLICATION IN BULGARIA Abstract  similar documents
T. Vekov
"... фармацевтических компаний при прохождении процедуры на включение в список разрешенных лекарств, затраты на которые ..."
 
Vol 10, No 4 (2014) PHARMACOECONOMIC ANALYSIS OF ANTIHYPERTENSIVE DRUG COMBINATIONS USE Abstract  similar documents
E. I. Tarlovskaya, Y. A. Balandina, N. S. Maximchuk-Kolobova
"... without ischemic heart disease (n=56) were included into the study. Blood pressure (BP) dynamics and cost ..."
 
Vol 16, No 3 (2020) Economic Burden of Hypertension in the Russian Federation Abstract  similar documents
Yu. A. Balanova, A. V. Kontsevaya, A. O. Myrzamatova, D. K. Mukaneeva, M. B. Khudyakov, O. M. Drapkina
"... in the RF in 2016 including direct costs and economic losses caused by decreased labor efficiency. Material ..."
 
Vol 13, No 2 (2017) THESES OF PSYCHOSOMATIC MEDICINE Abstract  similar documents
F. I. Belyalov
"... , increase healthcare costs. Antidepressants decrease severity of anxiety and depression, as well as diminish ..."
 
Vol 1, No 1 (2005) ASSESSMENT OF QUALITY OF GENERICS IN CARDIOLOGY: REALITY AND POSSIBILITIES Abstract  similar documents
V. V. Yakusevich
"... it possible to decrease the costs of treatment. From the other side with the advent of big number of copies ..."
 
Vol 7, No 5 (2011) COMPARATIVE EFFICACY AND SAFETY OF HYPOLIPIDEMIC THERAPY WITH GENERIC AND ORIGINAL MEDICINAL PRODUCTS OF SIMVASTATIN Abstract  similar documents
E. I. Tarlovskaya, Yu. A. Balandina, I. E. Sapozhnikova, N. S. Maksimchuk
"... , creatine phosphokinase were evaluated every 4 weeks. Cost-effectiveness ratio was calculated. Results. 11 ..."
 
Vol 6, No 6 (2010) EFFICACY AND SAFETY OF SINUS RHYTHM RESTORATION WITH AMIODARONE AND PROPAFENONE IN OUTPATIENTS, ECONOMIC ASPECTS (BASED ON DATA OF N.A. SEMASHKO NORTHERN MEDICAL CLINICAL CENTER) Abstract  similar documents
T. A. Istomina, E. V. Serdechnaya, L. A. Kulminskaya, B. A. Tatarskiy, E. V. Kazakevich, V. L. Lipskiy, S. I. Martyushov
"... ), and amiodarone 600-800 mg daily. The cost/effectiveness ratio (CER) was estimated. This ratio shows the cost ..."
 
Vol 7, No 5 (2011) ECONOMIC BENEFITS OF LEFT VENTRICULAR HYPERTROPHY REGRESSION IN PATIENTS WITH ARTERIAL HYPERTENSION Abstract  similar documents
E. I. Tarlovskaya, N. S. Maksimchuk, S. V. Malchicova, M. V. Avksentieva, I. E. Sapozhnikova, Y. A. Balandina
"... 516 772.42 RUR for every 1 000 patients. It would reduce the total costs per patient during 10 years ..."
 
Vol 3, No 5 (2007) CLINICAL AND PHARMACOKINETIC EQUIVALENCE OF ORIGINAL AND GENERIC AMLODIPINE IN PATIENTS WITH MILD-TO-MODERATE ARTERIAL HYPERTENSION Abstract  similar documents
N. A. Belolipetskiy, S. N. Tolpygina, J. B. Zverkov, V. V. Pisarev, I. E. Koltunov, V. G. Belolipetskaya, S. J. Martsevich
"... Amlorus and Norvasc, respectively. Cost of Amlorus therapy per patient was 221 rbl/month in comparison ..."
 
Vol 8, No 2 (2012) COMPARISON OF PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ORIGINAL AND GENERIC ENALAPRIL IN THE ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION Abstract  similar documents
O. P. Bobrova, M. M. Petrova
"... of cost minimization analysis. Results. Original enalapril dose necessary to achieve the target blood ..."
 
Vol 4, No 5 (2008) CLINICAL AND ECONOMICAL ASSESSMENTS OF METOPROLOL TARTRATE/SUCCINATE USAGE IN PATIENTS WITH ISCHEMIC HEART DISEASE Abstract  similar documents
M. V. Soura
"... ’s comparative cost analysis on metoprolol tartrate (Betaloc) and metoprolol succinate (Betaloc ZOK) usage ..."
 
Vol 12, No 5 (2016) Treatment Adherence as a New Choice Factor for Optimization of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation and Hemostatic Gene Polymorphisms Abstract  PDF (Eng)  similar documents
Yu. P. Skirdenko, A. V. Shustov, V. V. Zherebilov, N. A. Nikolayev
"... , получающими новые пероральные антикоагулянты (НОАК). Мутации гена CYP2C9 выявлены у 32,9%, VKORC1 – у 68,3%, а ..."
 
Vol 14, No 4 (2018) Physician’s Adherence to Clinical Guidelines for in-Hospital Anticoagulant Prescribing Abstract  similar documents
A. A. Chernov, E. V. Kleymenova, D. A. Sychev, L. P. Yashina, M. D. Nigmatkulova, V. A. Otdelenov, S. A. Payushchik
"... » group direct cost for inpatient AC therapy was significantly higher than in «adherent» group 4041 rubles ..."
 
Vol 5, No 4 (2009) CLINICO-ECONOMICAL ANALYSIS OF THE TREATMENT EFFICACY IN PATIENTS WITH ARTERIAL HYPERTENSION OF 1-2 DEGREES Abstract  similar documents
L. A. Haisheva, S. V. Shlyk, T. Y. Bykovskaya
"... was performed according to “cost-efficacy” approach at the end of 3 month therapy. Results. About 50 ..."
 
Vol 15, No 4 (2019) The Therapy with Oral Anticoagulants in Patients with Atrial Fibrillation in Outpatient and Hospital Settings (Data from RECVASA Registries) Abstract  similar documents
M. M. Loukianov, S. Yu. Martsevich, O. M. Drapkina, S. S. Yakushin, A. N. Vorobyev, K. G. Pereverzeva, A. V. Zagrebelnyy, V. Val. Yakusevich, V. Vl. Yakusevich, E. M. Pozdnyakova, T. A. Gomova, E. E. Fedotova, M. N Valiakhmetov, V. P. Mikhin, Yu. V. Maslennikova, E. Y. Andreenko, V. G. Klyashtorny, E. V. Kudryashov, E. Yu. Okshina, M. A. Panagopulu, S. A. Boytsov
"... % мужчин), в т.ч. варфарин – 817 пациентам (26%) и новые оральные антикоагулянты (НОАК) – 518 (16 ..."
 
Vol 15, No 2 (2019) Cardiovascular medicine prices as an indicator of access to medicines and their rational use Abstract  similar documents
C M. Razzakova, L. E. Ziganshina
"... procurement prices of these medicines in hospitals. Also we performed pharmacoeconomic cost-minimisation ..."
 
Vol 16, No 1 (2020) Deprescribing Antihypertensive Drugs in Patients of Older Age Groups Abstract  similar documents
O. D. Ostroumova, M. S. Cherniaeva, D. A. Sychev
"... and reduces the economic cost of treatment. Therefore, deprescribing of antihypertensive drugs can be used ..."
 
Vol 9, No 3 (2013) ECONOMIC EVALUATION OF COMBINED THERAPY OF ARTERIAL HYPERTENSION BY MARKOV’S MODELING Abstract  similar documents
N. S. Maksimchuk-Kolobova, E. I. Tarlovskaya, S. V. Malchikova
"... 1000 patients. It would reduce the total costs per patient during 10 years. V/A therapy is able to save ..."
 
Vol 8, No 2 (2012) THE "NEW" DRUG CLASSES IN THE TREATMENT OF CHRONIC HEART FAILURE AND THEIR EVIDENCE BASE Abstract  similar documents
S. N. Tereshchenko, I. V. Zhirov, A. G. Kochetov, O. V. Uspenskaya
"... to treatment, induces additional costs or may be a reason of new side effects. Additional (to standard therapy ..."
 
Vol 5, No 4 (2009) TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS Abstract  similar documents
L. N. Malay, A. N. Miroshnichenko, B. V. Sharykin, V. V. Konurovsky
"... , treatment costs and safety). The place of ACE inhibitors and ARB in modern therapy of cardiovascular ..."
 
Vol 13, No 1 (2017) MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE Abstract  similar documents
N. F. Puchinian, N. V. Furman, L. I. Malinova, P. V. Dolotovskaya
"...   затрат сил и времени для самообразования. Цель обзора – в краткой форме помочь практикующим врачам ..."
 
1 - 100 of 116 Items 1 2 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)